Literature DB >> 31159815

Correction to: Subclinical myocardial injury in patients with Facioscapulohumeral muscular dystrophy 1 and preserved ejection fraction - assessment by cardiovascular magnetic resonance.

Edyta Blaszczyk1,2, Ulrike Grieben3, Florian von Knobelsdorff-Brenkenhoff1,2,4, Peter Kellman5, Luisa Schmacht1,2, Stephanie Funk1,2, Simone Spuler3, Jeanette Schulz-Menger6,7.   

Abstract

In the original version of this article [1], published on 29 April 2019, there is 1 error in the 'Method' section of the article.

Entities:  

Year:  2019        PMID: 31159815      PMCID: PMC6545672          DOI: 10.1186/s12968-019-0541-8

Source DB:  PubMed          Journal:  J Cardiovasc Magn Reson        ISSN: 1097-6647            Impact factor:   5.364


Correction to: J Cardiovasc Magn https://doi.org/10.1186/s12968-019-0537-4 In the original version of this article [1], published on 29 April 2019, there is 1 error in the ‘Method’ section of the article. The original publication states: A sampling protocol with reduced sensitivity to heart rate was applied [15] before and 15 min after contrast media (0.15 mmol/kg body weight Gadoteriol) application (T1 native: 5 s(3 s)3 s; T1 post-contrast: 4 s(1 s)3 s(1 s)2 s; TE 1.1 ms and slice thickness 6 mm). However, the contrast media was Gadobutrol The corrected information is also repeated below: A sampling protocol with reduced sensitivity to heart rate was applied [15] before and 15 min after contrast media (0.15 mmol/kg body weight Gadobutrol) application (T1 native: 5 s(3 s)3 s; T1 post-contrast: 4 s(1 s)3 s(1 s)2 s; TE 1.1 ms and slice thickness 6 mm).
  1 in total

1.  Subclinical myocardial injury in patients with Facioscapulohumeral muscular dystrophy 1 and preserved ejection fraction - assessment by cardiovascular magnetic resonance.

Authors:  Edyta Blaszczyk; Ulrike Grieben; Florian von Knobelsdorff-Brenkenhoff; Peter Kellman; Luisa Schmacht; Stephanie Funk; Simone Spuler; Jeanette Schulz-Menger
Journal:  J Cardiovasc Magn Reson       Date:  2019-04-29       Impact factor: 5.364

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.